Forecast

The analysts' average price target is +8,75€ (+1,74%). The median is +8,75€ (+1,74%).

Buy	3
Hold	1
Sell	0

News Go to news feed

Growth worries weigh on Haleon shares after half‑year results

Haleon reported organic revenue growth of 2.6% for H1 2026 and revenue of around £5.55 billion, narrowly missing consensus estimates. Growth therefore remained well below the mid‑term target range of 4–6%, although organic growth accelerated to 3.1% in Q2. The company confirmed its outlook for 2026 and announced an interim dividend of 2.4p, but investors reacted negatively to the discrepancy with the targets and to cautious analyst comments. The stock fell about 2.2% to 371.5p and is trading well below its 52‑week high. » More on de.investing.com
FDA warns Haleon’s Alli can cause acute kidney injury; label updated

The FDA approved new label warnings for Haleon’s over-the-counter weight-loss pill Alli, citing rare risks including acute kidney injury, kidney stones and oxalate nephropathy that can be fatal if untreated. The updated drug facts instruct people with prior kidney disease or stones to consult a doctor and tell all users to stop taking Alli if they develop back or groin pain, blood in urine, painful urination or leg swelling. Alli’s label already advised caution for transplant recipients and people with gallbladder, pancreatic or interacting medication issues; orlistat (Alli/Xenical) has been used by an estimated 40 million people since 1999/2007 approvals. » More on forbes.com
Haleon executives buy shares via dividend reinvestment program

Haleon reports that CFO Dawn Allen acquired 2,596 ordinary shares on the London Stock Exchange on 19 May at £3.4022 each. CEO Brian McNamara on the same day bought 24,891 ordinary shares on the London Stock Exchange at £3.4022 and 4,415 ADS on the NYSE at $9.2446 each as a result of the dividend reinvestment. The transactions were disclosed under the Market Abuse Regulation and signed by Company Secretary Amanda Mellor. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Haleon PLC has already paid 0,11€ in dividends. The last payout was in May.

Financials

In the last quarter, Haleon PLC had revenue of 6.55b€ and net profit of 891.06m€

(EUR)	Jun 2026	YoY
Revenue	+6.55b	-
Gross profit	+4.33b	-
Net profit	+891.06m	-
EBITDA	+1.76b	-

Fundamentals

Metric	Value
Market capitalization	+38.64b€
Number of shares	4.40b
52-week high/low	+9,68€ - +7,42€
Dividend yield	+1,89%
Dividends TTM	+0,17€
Next dividend	+0,0551€
Beta	0,25
P/E ratio	+20,56
PEG ratio	+3,50
P/B ratio	+2,03
P/S ratio	+2,95

Company profile

Haleon plc beschäftigt sich mit der Forschung und Entwicklung, der Herstellung und dem Verkauf verschiedener Produkte für die Gesundheitsfürsorge in Nordamerika, Europa, dem Nahen Osten, Afrika, Lateinamerika und dem asiatisch-pazifischen Raum. Das Unternehmen bietet therapeutische Produkte in den Bereichen Mundgesundheit, Schmerzlinderung, Atemwegsgesundheit, Verdauungsgesundheit und andere Produkte sowie Vitamine, Mineralien und Nahrungsergänzungsmittel an. Zu seinem Markenportfolio gehören Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax und Centrum. Das Unternehmen war früher unter dem Namen DRVW 2022 plc bekannt und änderte im Februar 2022 seinen Namen in Haleon plc. Haleon plc wurde im Jahr 2021 gegründet und hat seinen Hauptsitz in Brentford, Vereinigtes Königreich.